Lineage Cell Therapeutics (LCTX) Current Deferred Tax Assets (2011 - 2012)
Lineage Cell Therapeutics (LCTX) reported Current Deferred Tax Assets of $712981.0 for Q3 2012, down 5.75% quarter-over-quarter from $756510.0 in Q2 2012.
Lineage Cell Therapeutics (LCTX) Current Deferred Tax Assets (2011 - 2012) Analysis & Trends
Lineage Cell Therapeutics has reported Current Deferred Tax Assets for 2 years, with the latest figure at $712981.0 in Q3 2012.
- For the quarter ending Q3 2012, Current Deferred Tax Assets changed N/A year-over-year to $712981.0; the trailing twelve-month figure through Sep 2012 stood at $712981.0 (changed N/A YoY), and the FY2011 full-year result was $843944.0, changed N/A from the prior year.
- Current Deferred Tax Assets for Q3 2012 stood at $712981.0, down from $756510.0 in the prior quarter.
- The five-year high for Current Deferred Tax Assets was $843944.0 in Q4 2011, with the low at $712981.0 in Q3 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Lineage Cell Therapeutics | 303.84 Mn | 239.94 Mn | 1.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2012 | 712,981.00 |
| Sep 30, 2012 | 712,981.00 |
| Jun 30, 2012 | 756,510.00 |
| Jun 30, 2012 | 756,510.00 |
| Dec 31, 2011 | 843,944.00 |
| Dec 31, 2011 | 843,944.00 |